Cookson Peirce & Co. Inc. Boosts Stock Position in Integer Holdings Co. (NYSE:ITGR)

Cookson Peirce & Co. Inc. boosted its holdings in Integer Holdings Co. (NYSE:ITGR) by 56.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 6,432 shares of the medical equipment provider’s stock after purchasing an additional 2,326 shares during the period. Cookson Peirce & Co. Inc.’s holdings in Integer were worth $852,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of ITGR. Eagle Asset Management Inc. purchased a new position in Integer in the third quarter worth $14,403,000. Laurus Investment Counsel Inc. purchased a new position in shares of Integer during the 4th quarter valued at $5,422,000. New York State Common Retirement Fund lifted its position in shares of Integer by 20.9% during the 4th quarter. New York State Common Retirement Fund now owns 232,569 shares of the medical equipment provider’s stock valued at $30,820,000 after buying an additional 40,158 shares during the last quarter. Bamco Inc. NY lifted its position in shares of Integer by 17.4% during the 3rd quarter. Bamco Inc. NY now owns 254,377 shares of the medical equipment provider’s stock valued at $33,069,000 after buying an additional 37,700 shares during the last quarter. Finally, Jane Street Group LLC lifted its position in shares of Integer by 23.3% during the 3rd quarter. Jane Street Group LLC now owns 151,397 shares of the medical equipment provider’s stock valued at $19,682,000 after buying an additional 28,572 shares during the last quarter. Hedge funds and other institutional investors own 99.29% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on ITGR shares. KeyCorp upped their price target on Integer from $144.00 to $154.00 and gave the company an “overweight” rating in a research report on Friday, January 24th. Citigroup upped their price target on Integer from $130.00 to $145.00 and gave the company a “neutral” rating in a research report on Wednesday, December 11th. Truist Financial upped their price target on Integer from $147.00 to $163.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. Oppenheimer cut Integer from an “outperform” rating to a “market perform” rating in a report on Friday, February 21st. Finally, Benchmark increased their price objective on Integer from $140.00 to $150.00 and gave the stock a “buy” rating in a report on Friday, February 21st. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $147.67.

Integer Price Performance

Shares of NYSE ITGR opened at $122.87 on Thursday. The firm has a market capitalization of $4.13 billion, a P/E ratio of 36.57, a P/E/G ratio of 1.72 and a beta of 1.13. The company has a quick ratio of 2.09, a current ratio of 2.95 and a debt-to-equity ratio of 0.62. The stock’s 50-day simple moving average is $136.01 and its two-hundred day simple moving average is $132.95. Integer Holdings Co. has a twelve month low of $107.11 and a twelve month high of $146.36.

Integer (NYSE:ITGR) last announced its earnings results on Thursday, February 20th. The medical equipment provider reported $1.43 earnings per share for the quarter, missing analysts’ consensus estimates of $1.46 by ($0.03). The business had revenue of $449.50 million during the quarter, compared to the consensus estimate of $446.28 million. Integer had a return on equity of 11.65% and a net margin of 6.92%. As a group, equities analysts anticipate that Integer Holdings Co. will post 6.01 EPS for the current fiscal year.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.